Start complement inhibition (eculizumab/ravulizumab)•Patient receives antimeningococal vaccination •Starts ravulizumab according to spc on ciprofloxacin prophylaxis •Complement testing: low C3,C4 and increased soluble C5b-9 •Genetic testing: no known complement-related variant •Patient responds to ravulizumab with normalization of laboratory values and no TMA-related event Would you stop complement inhibitor after 6 months? |
Map: TMA (792)
|
||
|
Review your pathway |
